

1 Supplementary Materials

2

3 **Search strategy**

4 The search strategy reported below refers to PubMed and has been converted to be run in
5 the other prespecified databases.

6 *Electronic database (PubMed)*

7 ("pharmacovigilance"[tiab] OR "Product Surveillance, Postmarketing"[mh] OR "Adverse Drug
8 Reaction Reporting Systems"[mh] OR "Adverse event reporting system"[tiab] OR
9 surveillance[ti] OR "safety surveillance"[tiab] OR "post-marketing surveillance"[tiab] OR
10 "postmarketing surveillance"[tiab] OR "drug surveillance"[tiab] OR "surveillance system"[tiab]
11 OR "surveillance database"[tiab] OR "reporting system"[tiab] OR "reporting database"[tiab])

12 AND

13 ("adr"[tiab] or "adrs"[tiab] or adverse event*[tiab] OR associat*[tiab] OR adverse drug event*
14 tiab] OR adverse drug reaction*[tiab] OR adverse drug effect*[tiab] OR adverse effect*[tiab]
15 OR side effect*[tiab] OR undesirable effect*[tiab] OR "drug-induced"[tiab] OR "drug
16 induced"[tiab] OR "drug-related"[tiab] OR "drug related"[tiab] OR "treatment-
17 emergent"[tiab] OR "drug safety"[tiab] OR "product safety"[tiab] OR "patient safety"[tiab] OR
18 "medicine safety"[tiab] OR safety issue*[tiab] OR safety problem*[tiab] OR safety
19 concern*[tiab] OR "tolerability"[tiab] OR "toxicity"[tiab] OR unexpected effect*[tiab] OR
20 unexpected event*[tiab] OR "safety"[tiab] OR "safe"[tiab] OR complication*[tiab] OR
21 "Chemically Induced"[sh] OR "adverse effects"[sh] OR "drug effects"[sh] OR

22 "complications"[sh] OR "drug interactions"[mh] OR "Drug-Related Side Effects and Adverse
23 Reactions"[mh])

24 AND

25 ("pharmacovigilance analysis"[tiab] OR signal*[tiab] OR "signal detection"[tiab] OR
26 alert*[tiab] OR trigger*[tiab] OR spontaneous report*[tiab] OR spontaneously report*[tiab]
27 OR event report*[tiab] OR safety report*[tiab] OR " Unknown ADR"[tiab] OR " Unknown
28 ADRs"[tiab])

29 NOT

30 ("retracted publication"[pt] OR "Editorial"[pt] OR "Comment"[pt] OR "Letter"[pt] OR
31 "News"[pt] OR "Surveys and Questionnaires"[majr] OR "Signal Transduction"[majr] OR
32 "Published Erratum"[pt])

33

34 *Grey literature: Google Scholar*

35 ("signal" OR "signals") AND ("side effect" OR "ADR" OR "adverse drug reaction" OR "adverse
36 event") AND "pharmacovigilance"

37

38 *Grey literature: signals publicly available on regulatory websites*

39 List of English language websites of drug regulatory agencies drawn from Onakpoya et al. [1]
40 adapted for searches of signals of adverse drug reactions with medicinal products.

41

42 Numbered items followed by a letter were added by DS after consultation with Uppsala
43 Monitoring Centre's Global Services and represent additional members of the WHO
44 Programme for International Drug Monitoring.

45

46 1. **Australia:** Therapeutic Goods Administration (TGA): [https://www.tga.gov.au/all-](https://www.tga.gov.au/all-alerts#summary-s)
47 [alerts#summary-s](https://www.tga.gov.au/all-alerts#summary-s)

48 2. **Bahamas:** Bahamas National Drug Agency (BNDA):
49 <http://www.corp.phabahamas.org/hospitals-services/bnda/>

50 3. **Bhutan:** Drug Regulatory Authority: <http://dra.gov.bt/>

51 4. **Botswana:** Ministry of Health, Republic of Botswana: <http://www.moh.gov.bw/> (no
52 Medicines Regulatory Authority)

53 5. **Canada:** Health Canada Drug Product Database (DPD): [http://www.hc-sc.gc.ca/dhp-](http://www.hc-sc.gc.ca/dhp-mps/prodpharma/databasdon/index-eng.php)
54 [mps/prodpharma/databasdon/index-eng.php](http://www.hc-sc.gc.ca/dhp-mps/prodpharma/databasdon/index-eng.php)

55 6. **European Union:** European Medicines Agency (EMA): <http://www.ema.europa.eu/ema/>

56 7. **Gambia:** Medicine Regulatory Authority: <http://www.mca.gm/>

57 8. **Ghana:** Ghana Food and Drugs Authority (FDA): <http://www.fdaghana.gov.gh/>

58 8a. **Hong Kong:** Hong-Kong's Department of Health Drug Office
59 <http://www.drugoffice.gov.hk/eps/do/en/level.html>

60 9. **India:** Central Drugs Standard Control Organization (CDSCO):
61 <http://www.cdsc0.nic.in/forms/Default.aspx>

62 10. **Jamaica:** Ministry of Health, Kingston, Jamaica: <http://moh.gov.jm/?s=drug+regulation>

- 63 10a. **Japan's** Pharmaceuticals and Medical Devices Authority:
- 64 <https://www.pmda.go.jp/english/>
- 65 11. **Kenya:** Pharmacy and Poisons Board, Kenya: <http://pharmacyboardkenya.org/>
- 66 11a. **Korea (Republic of):** Korea Institute of Drug Safety and Risk Management
- 67 <https://www.drugsafe.or.kr/en/index.do>
- 68 12. **Liberia:** Liberian Medicines Health Products Regulatory Authority:
- 69 https://healthresearchweb.org/en/liberia/research_regulation_4284
- 70 12a **Malaysia:** National Pharmaceutical Regulatory Agency
- 71 <https://www.npra.gov.my/index.php/en/>
- 72 13. **Malta:** Malta Medicines Authority: <http://www.medicinesauthority.gov.mt/home?l=1>
- 73 14. **Namibia:** Namibia Medicines Regulatory Council: <http://www.nmrc.com.na/>
- 74 15. **New Zealand:** New Zealand Medicines and Medical Devices Safety Authority:
- 75 <http://www.medsafe.govt.nz/index.asp>
- 76 16. **Nigeria:** National Agency for Food and Drug Administration and Control (NAFDAC):
- 77 <http://www.nafdac.gov.ng/>
- 78 17. **Pakistan:** Drug Regulatory Authority of Pakistan (DRAP):
- 79 <http://www.dra.gov.pk/gop/index.php?q=aHR0cDovLzE5Mi4xNjguNzAuMTM2L2RyYXAv>
- 80 18. **Philippines:** Food and Drug Administration, Philippines (FDA): <https://www.fda.gov.ph>
- 81 19. **Rwanda:** Ministry of Health, Republic of Botswana:
- 82 <http://www.moh.gov.rw/index.php?id=2> (no Medicines Regulatory Authority)

- 83 19a. **Saudi Arabia:** Saudi Food and Drug Administration
- 84 <https://www.sfda.gov.sa/En/Pages/default.aspx>
- 85 20. **Sierra Leone:** Pharmacy Board of Sierra Leone: <http://www.pharmacyboard.gov.sl/>
- 86 21. **Singapore:** Health Sciences Authority: <http://www.hsa.gov.sg/content/hsa/en.html>
- 87 22. **South Africa:** South Africa Medicines Control Council (MCC): <http://www.mccza.com/>
- 88 23. **Sri Lanka:** Cosmetics, Devices and Drug Regulatory Authority: <http://www.cdda.gov.lk/>
- 89 24. **Tanzania:** Tanzania Food and Drugs Authority (TFDA): <http://www.tfda.or.tz/>
- 90 25. **Thailand:** Food and Drug Administration, Thailand:
- 91 <http://www.fda.moph.go.th/eng/index.stm>
- 92 26. **Trinidad and Tobago:** Ministry of Health, Trinidad and Tobago:
- 93 <http://www.health.gov.tt/sitepages/default.aspx?id=93>
- 94 27. **Uganda:** National Drug Authority: <http://www.nda.or.ug/>
- 95 28. **United Kingdom:** Medicines and Healthcare products Regulatory Agency (MHRA):
- 96 [https://www.gov.uk/government/organisations/medicines-and-healthcare-products-](https://www.gov.uk/government/organisations/medicines-and-healthcare-products-regulatory-agency)
- 97 [regulatory-agency](https://www.gov.uk/government/organisations/medicines-and-healthcare-products-regulatory-agency)
- 98 29. **USA:** Food and Drug Administration (FDA): <http://www.fda.gov/>
- 99 30. **Zambia:** Pharmaceutical Regulatory Authority (PRA): <http://www.zamra.co/>
- 100 31. **Zimbabwe:** Medicines Control Authority of Zimbabwe (MCAZ): <http://www.mcaz.co.zw/>
- 101

102 **References**

- 103 1. Onakpoya IJ, Heneghan CJ, Aronson JK. Post-marketing withdrawal of anti-obesity
104 medicinal products because of adverse drug reactions: a systematic review. BMC
105 Medicine. 2016;14(1):191.
106